Guildford, UK, 23 April 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L), the leading UK-based stem cell therapy company, today announces that, in order to manage the increasing breadth of the Company’s clinical, operational and commercial activities, the Board of the Company is to be reconfigured with the appointment of a new Chief Executive Officer.